Format

Send to

Choose Destination
Cutis. 2016 Oct;98(4):253-256.

Low-dose radiotherapy for primary cutaneous anaplastic large-cell lymphoma while on low-dose methotrexate.

Author information

1
Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, USA.
2
Department of Dermatology, Stanford University School of Medicine, California, USA.
3
Department of Radiation Oncology, Chester County Hospital, West Chester, Pennsylvania, USA.

Abstract

Primary cutaneous anaplastic large-cell lymphoma (pcALCL) is part of a spectrum of CD30+ primary cutaneous lymphoproliferative disorders (pcLPDs) that also includes lymphomatoid papulosis (LyP). Localized radiotherapy at doses of 34 to 44 Gy is first-line treatment of pcALCL, but the use of low-dose radiotherapy for pcALCL has not been reported. We present the case of a patient with a history of pcALCL/LyP who was treated with low-dose radiotherapy while on oral low-dose methotrexate (MTX) once weekly. This report suggests that low-dose radiotherapy can be an effective palliative treatment of pcALCL. Low-dose radiotherapy may offer certain advantages over traditional radiotherapy, such as a more economical and efficient treatment for patients, potentially fewer short-term and long-term side effects, and the potential for concomitant use with low-dose MTX.

PMID:
27874877
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Frontline Medical Communications Inc
Loading ...
Support Center